PRESSEMITTEILUNGEN

——————————————————————————– Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. ——————————————————————————– Company Information/New Products/molecular diagnostics Subtitle: Conference Call Scheduled for today, 9thDecember 2011 at 4 pm CET Berlin, Germany, and Seattle, WA, U.S.A., December 9, 2011 (euro adhoc) – Epigenomics AG (Frankfurt Prime Standard: ECX), the cancer [...]

Continue reading

Adhoc, Berlin Germany, Cancer Cases, Clinical Performance, Clinical Validation, Colonoscopy, Colorectal, Colorectal Cancer, Diagnostic Company, Disease Specificity, Eans, Epigenomics Ag, Independent Laboratories, Molecular Diagnostics, Plasma Samples, Prime Standard, Regulatory Approval, Screening Guidelines, Study Subjects, Validation Study

——————————————————————————– Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. ——————————————————————————– Company Information/New Products/molecular diagnostics Subtitle: Study provides clinical evidence for CE-marking in Europe and paves way to US pivotal clinical trial for submission to FDA before year-end Berlin, Germany, and Seattle, WA, USA, September 19, 2011 [...]

Continue reading

Adhoc, Ag Reports, Berlin Germany, Cancer Cases, Clinical Evidence, Colonoscopy, Colorectal, Colorectal Cancer, Epigenomics, Food And Drug Administration, Molecular Diagnostics, Pivotal Clinical Trial, Prime Standard, Product Validation, Seattle Wa Usa, Second Generation, Significant Improvement, Specificity, Therapeutic Interventions, Validation Study

Irvine, California and Amsterdam (ots/PRNewswire) – Agendia, a world leader in molecular cancer diagnostics, announced today that together with principal investigators from Spain, the UK, and the Netherlands, it has published the first independent validation study of its colon cancer recurrence test “ColoPrint” in the Journal of Clinical Oncology. The authors conclude that ColoPrint significantly [...]

Continue reading

Cancer Diagnostics, Classifier, Colon Cancer, Colon Cancer Recurrence, Colorectal Cancer, Cross Validation, Free Survival, Gene Expression, Human Genome, Independent Set, Independent Validation, Journal Of Clinical Oncology, Molecular Cancer, Oligonucleotide Arrays, Principal Investigators, Risk Criteria, Tumor Tissue, Univariate Analysis, Validation Procedure, Validation Study

Presentation at ASCO – NCI – EORTC Molecular Markers Meeting ——————————————————————————– Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. ——————————————————————————– Company Information/Molecular diagnostics Subtitle: Presentation at ASCO – NCI – EORTC Molecular Markers Meeting Berlin and Seattle – October 20, 2010 (euro adhoc) – Epigenomics AG’s [...]

Continue reading

Arup Laboratories, Biomarker, Cancer Cases, Clinical Validation, Colorectal Cancer, Dna Methylation, Ecx, Epigenomics Ag, Free Dna, Hollywood Fl, Independent Validation, Laboratory Service, Molecular Diagnostics, Molecular Markers, Poster Presentation, Premalignant Lesions, Prime Standard, Supportive Tissue, Validation Results, Validation Study

Biomarker mPITX2 for prostate cancer prognostic application successfully validated First clinical laboratory in Germany to start offering mPITX2 testing service ——————————————————————————– Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. ——————————————————————————– new product/research/Molecular diagnostics Press release, Berlin, Germany and Seattle, WA, USA, May 29, 2009 (euro adhoc) [...]

Continue reading

Berlin Germany, Cancer Detection, Disease Recurrence, Dna Methylation, Eans, Epigenomics Ag, Molecular Diagnostics, New Product Research, Orlando Florida Usa, Poster Presentation, Prime Standard, Prostate Cancer, Prostate Cancer Patients, Prostate Cancer Prognosis, Prostate Cancer Risk, Prostatectomy, Rational Design, Risk Groups, Seattle Wa Usa, Validation Study

Patents cover biomarker mPITX2 for prostate and breast cancer indications ——————————————————————————– Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. ——————————————————————————– new product/molecular diagnostics Berlin, Germany, and Seattle, WA, USA, May 13, 2009 (euro adhoc) – Epigenomics AG (Frankfurt Prime Standard: ECX), a molecular diagnostics company focusing [...]

Continue reading

American Urological Association, Breast Cancer, Breast Cancer Patients, Cancer Detection, Cancer Indications, Disease Recurrence, Dna Methylation, Duke University, Epigenomics Ag, European Patent Office, Patent And Trademark Office, Patent Application, Patent Applications, Prostate Cancer, Prostate Cancer Prognosis, Seattle Wa Usa, United States Patent, United States Patent And Trademark Office, Urology Community, Validation Study

(pressebox) Dresden, Germany, 19.03.2009, Cenix BioScience GmbH, a leading RNA interference (RNAi)-focused contract research organization, today announced that it has initiated a second research project under its existing framework research agreement with AstraZeneca Pharmaceuticals LP, one of the world’s leading pharmaceutical companies. The new project will focus on detailed cell-based studies to further advance the [...]

Continue reading

Analysis Platform, Astrazeneca, Astrazeneca Pharmaceuticals Lp, Cellular Functions, Contract Research Organization, Definiens, Dresden Germany, Echeverri, Framework Research, Healthcare Business, High Throughput, International Healthcare, Prescription Medicines, Rna Interference, Target Candidates, Target Discovery, Target Validation, Therapeutic Development, Therapeutic Drug, Validation Study